Delegates Attending OIS@ASRS

  • Tony Adamis, MD, Global Head, I2O & Metabolism, Clinical Science – Genentech
  • Rajat Agrawal, Sr. Medical Director, Global R&D – Santen
  • Sean Ainsworth, CEO – RetroSense Therapeutics
  • Tirso Alonso, Senior Director, Medical Affairs – Allergan
  • Roger Anderson, Managing Partner – BioQuest
  • Andrew Antoszyk, MD – CEENTA
  • Syed Askari, Founder & President – Medicus Biosciences
  • Neil Aubuchon, VP, Global Marketing – Santen
  • Robert Avery, MD, Founder – California Retina Consultants
  • Richard Awdeh, MD, Professor – Bascom Palmer Eye Institute
  • Carl Awh, MD – Tennessee Retina
  • Megan Baldwin, CEO & Managing Director – Opthea
  • Simon Barnard, Director – Migdal Consultants, Ltd
  • Sam Barone, SVP, Clinical Development – Adverum Biotechnologies
  • Michele Barrett, Regional Sales Manager – Retina Specialist
  • Susan Benton, Head of Ophthalmology Business Development – Shire
  • Michael Berry, President & CEO – Optimal Acuity Corporation
  • Cagri Besirli, Assistant Professor – University of Michigan
  • Kumaril Bhargava, Executive Director – Merck
  • Tanya Bhavnani, Vice President – BTIG
  • Lanya Bingo, Manager of Strategic Accounts – Notal Vision
  • Jill Blim, Executive Vice President – ASRS
  • Mark Blumenkranz, MD, Professor of Ophthalmology – Byers Eye Institute, Stanford University
  • Zachary Bodnar, Fellow – Byers Eye Institute at Stanford
  • Ryan Bouchard, Director, Medical Devices – Ora
  • Maryline Boulay, Director Investor Relations – Salutaris Medical Devices
  • Jeffrey Boyd, Medical Director – Eye Care of Delaware
  • Shelley Boyd, MD
  • David Boyer, MD, – Retina-Vitreous Associated Medical Group
  • Rose Wynne Brooks, VP, Marketing – Carl Zeiss Meditec
  • Eric Buckland, General Manager – Bioptigen / Leica Microsystems
  • Janet Burk, Publisher – Bryn Mawr Communications
  • Jeff Burris
  • Adnan Butt, Senior Biotech Analyst – RBC Capital Markets
  • Abby Cahn, Associate Director New Products Marketing – Regeneron Pharmaceuticals
  • Grace Chang, Therapeutic Unit Expert – Alcon
  • Andy Chang, SVP, General Manager, US Surgical – Bausch + Lomb
  • Yuan Chang, Senior Director – Shire
  • Steve Charles, Chairman – Charles Retina Institute
  • Frank Chen, Innovation Project – Santen
  • Hubert Chen, MD, Chief Medical Officer – Pfenex
  • Jeff Cleland, President & CEO – Graybug Vision
  • Scott Cooper, CFO – Allegro Ophthalmics
  • Jay Cormier, CEO – Ocutrx
  • Emmett Cunningham, Jr., MD, PhD, MPH, Partner – Clarus
  • Ocar Cuzzani, MD – BioTime
  • Anupam Dalal, Managing Director – Kearny Venture Partners
  • Michelle Dalton, Contributing Writer – Dalton & Associates/Eye On Innovation
  • Donald D’Amico, MD, Professor & Chairman – Weill Cornell Medical College
  • Atul Dandekar, Lifecycle Leader – Roche
  • Eugene de Juan, MD, Founder & Vice-Chairman – ForSight Labs
  • Elisabet de los Pinos, CEO – Aura Biosciences
  • Roberto Deger, Chief Financial Officer – Carl Zeiss Meditec
  • Mitchell deLong, VP, Chemistry – Aerie Pharmaceuticals
  • Dhaval B. Desai, PhD, VP, Medical Affairs – Aerpio Therapeutics
  • Casey Dietrich, Academic Account Manager – Alcon
  • Lazar Dimitrov, PhD, Associate – Clarus
  • Zachary Dios, Principal Engineer R&D – Alcon
  • Peter Downs, Writer/Analyst – Market Scope
  • Heinrich Dreyer, VP, Medical Division Leica Microsystems – Leica Microsystems
  • Charles du Mee, Founder & CDO – Redwood Pharma
  • Pravin Dugel, MD, – Retinal Consultants of Arizona
  • Jay Duker, MD, Founder – Hemera Biosciences
  • Jacque Duncan, MD, – UCSF School of Medicine
  • Lisa Edone, VP, Marketing – Restoration Robotics
  • Andrew ElBardissi, Principal – Longitude Capital
  • Signe Erickson, SVP, Product Development – ForSight VISION4
  • Genevieve Fay, Director, Marketing – Carl Zeiss Meditec
  • Scott Ferguson, CEO – Aptitude Medical Systems
  • Phil Ferrone, MD, – Long Island Vitreo Retinal
  • Donald Fishbein, President – Evolve Therapeutics
  • David Fisher, VP, Marketing – Bausch + Lomb
  • Forrest Fleming, CEO – TrueVision Systems
  • Cedric Francois, CEO – Apellis Pharmaceuticals
  • Brad Fundingsland, President – The Fundingsland Group
  • Kunihiko Furuyama, General Manager, Corporate Planning Group – Santen
  • Joseph Gardner, President & CEO – Aerpio Therapeutics
  • Omar Gaya, Strategic Intelligence – Regeneron Pharmaceuticals
  • Bob Gibson, VP, Product Planning & Management – Topcon
  • Ron Gilliland, President & CEO – OCULUS Surgical
  • Andrew Gitkin, Head of West Coast Investment Banking – Piper Jaffray
  • Jade Gold, VP, Sales & Marketing – Insight Instruments
  • John Gonzales, MD, Assistant Professor – F.I. Proctor Foundation, University of California San Francisco
  • Adrienne Graves, PhD, Independent Director – Akorn
  • Michele Gray, Marketing & Communications – Allegro Ophthalmics
  • Robert Greenberg, Chairman – Second Sight Medical Products
  • William Greene, CEO – Iconic Therapeutics
  • Gregory Grunberg, Managing Director – Longitude Capital
  • Frederic Guerard, Worldwide Business Franchise Head, Ophthalmology – Alcon
  • Adam Gundaker, President & COO – Ethis Communications
  • Alan Guralnick, President – Evolve Medical Education
  • Larry Haimovitch, CEO – Haimovitch Medical Technology Consultants
  • Philip Haldar – Alimera Sciences
  • Paul Hallen, Global Head, Surgical Vitreoretinal & Glaucoma – Alcon
  • Ralph Hanahan, Managing Director – Cain Brothers
  • Tarek Hassan, MD, – Associated Retinal Consultants
  • Peggy Hawkins, BD & Venture Management – Santen
  • Rob Haynes, Acting Head, Global Market Research – Santen
  • Theresa Heah, VP, Clinical Research & Medical Affairs – Aerie Pharmaceuticals
  • Chuck Hess, VP, US Surgical Marketing – Bausch + Lomb
  • Takashi Hibi, General Manager, Global Business Development – Santen
  • David Hollander, Chief Medical Officer – Ora
  • Terrie Hopton, Manager, Business Development & Special Projects – Promedica International
  • Ken Howling, Chief Financial Officer – Translatum Medicus
  • David Huang, MD, PhD, Peterson Professor of Ophthalmology & Professor of Biomedical Engineering – Oregon Health & Science University
  • Mark Humayun, Professor of Ophthalmology – University of Southern California
  • Juan Ivaldi, VP, Biomedical R&D – Nikon Research Corporation of America
  • Peter Jarrett, CSO – Ocular Therapeutix
  • Scott Jones, President – Notal Vision
  • Stephen Judd, President – Cativer Bio Insights
  • J. Michael Jumper, MD, – West Coast Retina
  • Peter Kaiser, MD, Professor of Ophthalmology – Cole Eye Institute
  • Ripple Kakkar, Product Director, Retina – Allergan
  • Vishal Kapoor, Director, Business Development – Ophthotech
  • Hampar Karageozian, CEO – Allegro Ophthalmics
  • Vicken Karageozian, MD, President & Chief Medical Officer – Allegro Ophthalmics
  • Peter Karth, Associate Professor – Byers Eye Institute at Stanford
  • Elo Kent, Head, Global Innovation Office – Santen
  • Richard Kirkner, Editor – Retina Specialist
  • Gilbert Kliman, MD, Managing Director – InterWest Partners
  • Casey Kopczynski, Chief Scientific Officer – Aerie Pharmaceuticals
  • Theresa Kramer, MD, CEO & CMO – Ocuflow
  • Jordan Kramer, Director – Kaiser Permanente Ventures
  • Ralf Kuschnereit, PhD, SVP, Ophthalmic Systems Division – Carl Zeiss Meditec AG
  • Michael Lachman, Founder – EyeQ Research
  • Jeff Landau, VP, Business Development – Catalyst Biosciences
  • William Landbein, Senior Writer, Life Sciences & Healthcare – Mergermarket
  • Andrew Layton, Director, Health Economics & Outcomes Research – Quorum Consulting
  • Ian Leitch, Director, Clinical Research – Opthea
  • Leonid Lerner, President – OcuJect
  • Neil Levine, Executive Director Marketing – Regeneron Pharmaceuticals
  • Marsha Link, PhD, Principal – Link Consulting
  • William Link, PhD, Managing Director – Versant Ventures
  • Andrew Liu, Senior Strategist, Corporate Development Division – Santen
  • Timothy Lovell, President & CEO – Calpain Therapeutics
  • Peter Luloh, President – Insight Instruments
  • Angela Macfarlane, CEO – ForSight VISION4
  • Edwin Madison, Chief Scientific Officer – Catalyst Biosciences
  • John Magliocchetti, Senior Director Ophthalmology New Products Marketing – Regeneron Pharmaceuticals
  • Mark Maire, EVP Sales & Business Development – TrueVision Systems
  • Da Man, Manager, Corporate Planning Group – Santen
  • Rose Mastracci, Manager – Genentech
  • Jim Mazzo, Global President of Ophthalmology – Carl Zeiss Meditec
  • Jim McCollum, Co-Founder & Board Member – Presbyopia Therapies
  • Casey McGlynn, Life Sciences Group – Wilson Sonsini Goodrich & Rosati
  • Terrance McGovern, CEO – Kato Pharmaceuticals
  • Fred McMillan
  • Susanne Medeiros, Managing Editor, ONE Network – AAO
  • Scott Meyer, Director, Strategic Business Development – Carl Zeiss Meditec
  • Tom Mitro, COO & President – Aerie Pharmaceuticals
  • Ludwin Monz, PhD, President & CEO – Carl Zeiss Meditec AG
  • Vasiliana Moussatos, Managing Director – Wedbush
  • Christian Mueller, CFO – Carl Zeiss Meditec AG
  • Toshio Murata, Senior RA/QA Manager – Nidek
  • Michael Murray, Associate – BVF
  • Dan Myers, CEO – Alimera Sciences
  • Kester Nahen, PhD, Managing Director – Heidelberg Engineering
  • Joel Naor, Vice President Clinical Research & Development Operations – Kodiak Sciences
  • Babak Nemati, President & CEO – Strategic Intellegence
  • Esther Newman, Marketing Analytics & Strategy Manager – Genentech
  • Takashi Noaki, US Liason – Santen
  • Jonathan Norris, Managing Director – Silicon Valley Bank
  • Michael O’Rourke, President – Scotia Vision
  • Susan Orr, Chief Medical Officer – Notal Vision
  • Quinton Oswald, CEO – Notal Vision
  • Stephen J. Pakola, MD, Chief Medical Officer – Aerpio Therapeutics
  • Ram Palanki, VP, Strategic Marketing & Sales – Santen
  • Udit Patel, Principal, Healthcare Investment Banking – Piper Jaffray
  • Vincent Michael Patella, VP, Professional Affairs – Carl Zeiss Meditec
  • J.P. Peltier, Global Head, Healthcare Investment Banking – Piper Jaffray
  • Mickey Pentecost, Principal Scientist – Cell Care Therapeutics
  • Anton Petrov, COO – Mitotech S.A.
  • John Pollack, MD, – Illinois Retina Associates
  • Clare Price, Director, Clinical Development – Opthea
  • Richard Purvis, Head, MTC – Alcon/Novartis
  • Angelo Rago, SVP, Innovation & Operations – Carl Zeiss Meditec
  • Ryan Rhodes, President & CEO – Restoration Robotics
  • Calvin Roberts, MD, SVP & Chief Medical Officer – Bausch + Lomb
  • Karen Roman, Editor-in-Chief, Retina Today – Bryn Mawr Communications
  • Steven Sanislo, MD, – Byers Eye Institute
  • Namrata Saroj, Senior Medical Director – Regeneron Pharmaceuticals
  • Tracy Saxton, PhD, Investment Director – Roche Venture Fund
  • Baldo Scassellati Sforzolini, SVP, Clinical Development – Allergan
  • Ira Schachar, MD, Assistant Professor – Byers Eye Institute At Stanford
  • Lukas Scheibler, EVP, Research & Development – Acucela
  • Rhett Schiffman, CMO – Envisia Therapeutics
  • Joshua Schimmer, MD, Sr. Research Analyst – Piper Jaffray
  • Wayne Schnarr, Chief Business Officer – Translatum Medicus
  • Susan Schneider, VP, Therapeutic Area Head – Allergan
  • Daniel Schwartz, MD, – UCSF School of Medicine
  • Charles Semba, Chief Medical Officer – Graybug Vision
  • Luca Sergio, CEO & Owner – Ethis Communications
  • Christy Shaffer, PhD, General Partner – Hatteras Venture Partners
  • Naveed Shams, Head of Global R&D & Chief Scientific Officer – Santen
  • Aron Shapiro, Senior Vice President – Ora
  • Denise Sheehan, Global BOTE Therapy & OPSIRIA Brand Leader – Santen
  • Victor Shifrin, CEO – Pamdeca
  • Ken Shimokawa, Director & Head – Santen
  • Kuldev Singh, MD, Professor, Ophthalmology & Director, Glaucoma Service – Stanford University School of Medicine
  • Stephen J. Smith, MD, Vitreoretinal Surgery Fellow – Byers Eye Institute
  • Michael Smolinsky, Chief Content Officer – Ethis Communications
  • Matthew Snakenberg, Head, Global BD&L – Alcon
  • Nicolas Sohl, CEO – Cell Care Therapeutics
  • Jay Stewart, MD, – UCSF School of Medicine
  • Shannon Stoddard, President & CEO – Promedica International
  • Ivo Stoilov, Medical Director – Genentech
  • Caroline Stout, Investor – EcoR1 Capital
  • Brian Strem, CEO – Okogen
  • Alice Swinton, Director Global Communications – Carl Zeiss Meditec
  • Jonathan Talamo, Chief Medical Officer – Ocular Therapeutix
  • James Taylor, CEO – 2CTech
  • John Thompson, MD, Partner – Retina Specialists
  • Trex Topping, MD, Medical Director, OCB, Retired – Ophthalmic Consultants of Boston
  • Cynthia Toth, MD, Joseph AC Wadsworth Professor of Ophthalmology & Professor of Biomedical Engineering – Duke University
  • Burton Tripathi, CTO – TrueVision Systems
  • Catherine Truitt, Head, Search & Evaluation Surgical – Alcon
  • Lisa Tuomi, Senior Medical Science Director – Genentech
  • Ramin Valian, VP, Retina & Customer Innovation – Allergan
  • Sherri Van Everen
  • Dave Van Meter, President & CEO – Ivantis
  • Rose Verhoeven, Executive Director, Nonclinical – Envisia Therapeutics
  • Gaurav Vij, Assoc. Director, Business Development – Shire
  • Alex Virgilio, Analyst – PFM
  • Jeda Voska, Product Development Coordinator – Kato Pharmaceutials
  • Greg Wade, Managing Director – BTIG
  • Justin Waney, Investment Banking Analyst, Healthcare – Piper Jaffray
  • Conrad Wang, Principal – HealthCare Royalty
  • Jason Weems, Head, Global BD&L Vision Care – Alcon
  • Jeff Weinhuff, Managing Partner – Visionary Venture Fund
  • Cameron Wheeler, Principal – Deerfield Management
  • Delbert White, President – CamTek
  • Julia Williams, Sr. Director Global Strategic Alliance Management – Ora
  • Patrick Witham, President & CEO – Paragon BioTeck
  • Troy Wu, MD, Director, Business Development – Abbott Medical Optics
  • Steven Yeh, Associate Professor of Ophthalmology – Emory Eye Center
  • Lingfeng Yu, Director – Alcon
  • Bob Zatarain, VP, Business Development – OCULUS Surgical